Esperion Therapeutics, Inc. (ESPR) Dividend History

Esperion Therapeutics, Inc. (ESPR) is a pharmaceutical company focused on developing and commercializing oral lipid-lowering medicines to treat patients with high cholesterol and related cardiovascular conditions. Founded in 2008, the company specializes in therapies targeting elevated LDL cholesterol through innovative oral agents, aiming to provide additional options for patients who require more effective lipid management.

3891 Ranchero Drive, Suite 150, Ann Arbor, MI, 48108
Phone: 734-887-3903
Website: https://www.esperion.com

Dividend History

Esperion Therapeutics, Inc. currently does not pay dividends

Company News

Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference

Esperion, a commercial-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025. The company will provide a live webcast of the event on its investor and media section.

GlobeNewswire Inc.
Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Esperion announced new research supporting its lead development candidates for the treatment of primary sclerosing cholangitis (PSC), a rare and progressive liver disease. The company's next-generation ACLY inhibitor discovery program has shown promising preclinical results in reducing liver injury, inflammation, and fibrosis.

GlobeNewswire Inc.
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Esperion, a biopharmaceutical company, will host an R&D Day to showcase its research and development strategy, including advancements in ATP citrate lyase (ACLY) biology and its therapeutic potential in various diseases.

GlobeNewswire Inc.
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

Esperion reported strong revenue growth in Q4 2024, driven by increased prescription demand and global expansion. The company is focused on continued revenue growth, reaching profitability, and portfolio expansion. Esperion also announced the development of triple combination products with bempedoic acid in the U.S.

GlobeNewswire Inc.
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Esperion Therapeutics, a commercial-stage biopharmaceutical company, will report its third quarter 2024 financial results on March 4, 2025. The company will host a webcast to discuss the results and provide business updates.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 01:01:32 UTC